In 2017, the global plasma fractionation market was valued at $24bn and is expected to grow at a CAGR of 9.0% in the first half of the forecast period. In 2017, the immunoglobulins submarket held 44.0% of the global plasma fractionation market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 172-page report you will receive 91 tables and 98 figures– all unavailable elsewhere.
The 172-page report provides clear detailed insight into the global plasma fractionation market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Plasma Fractionation market forecasts from 2018-2028
• This report also breaks down the revenue forecast for the global plasma fractionation market by type of product: • Immunoglobulins • Albumins • Clotting Factors • Hyperimmune Globulins • Alpha 1 Antitrypsin Inhibitors (A1PI) • C-1 • Others
• This report also breaks down the revenue forecast for the global plasma fractionation market by type of application: • Primary Immune Deficiency (PID) • Secondary Immune Deficiency (SID) • Idiopathic Thrombocytopenic Purpura (ITP) • Cardiac & Surgery • Emergency Medicine • Haemophilia
• This report also breaks down the revenue forecast for the global plasma fractionation market by regional market: • North America • Europe • Latin America • Asia-Pacific • Middle East & Africa
• This report also breaks down the revenue forecast for the global plasma fractionation market by national market: • US • Canada • UK • Germany • France • Spain • Italy • Rest of Europe • Japan • Rest of APAC
• Our study discusses the selected leading companies that are the major players in the plasma fractionation industry: • Biotest • CSL • Grifols • Kedrion • LFB • OctaPharma • Shire/Baxalta • Others
• Our study gives qualitative analysis of the plasma fractionation market. It discusses factors that drive and restrain the market
• Other information included in this report: • Type of plasma processed in Europe from 1996 – 2012 (3-year increment) for non-profit organizations (source plasma vs recovered plasma, in thousand liters) • Type of plasma processed in Europe from 1996 – 2012 (3-year increment) for commercial companies (source plasma vs recovered plasma, in thousand liters) • Cost of plasma protein in Canada by product • Canadian plasma shipments for fractionation by source • Immunoglobulin-monthly distribution and 12-month rolling average distribution (2016/2017) for: the US, the UK, Germany, Italy, Spain, Austria, Finland, Greece, Norway, Portugal, Sweden, Switzerland • Albumin 5%-monthly distribution and 12-month rolling average distribution (2016/2017) for the US
Visiongain’s study is intended for anyone requiring commercial analyses for the global plasma fractionation market. You find data, trends and predictions.
Table 8.11 Global Plasma Fractionation Rest of APAC’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.1 Global Plasma Fractionation Rest of CSL’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.2 Global Plasma Fractionation Rest of Shire/Baxalta’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.3 Global Plasma Fractionation Rest of Grifols Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.4 Global Plasma Fractionation Rest of OctaPharma’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.5 Global Plasma Fractionation Rest of Biotest’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.6 Global Plasma Fractionation Rest of LFB’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.7 Global Plasma Fractionation Rest of KEDRION’s Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 9.8 Global Plasma Fractionation Rest of Other Companies Market Forecast 2017-2028 ($m, AGR %, CAGR %)
Table 10.1 Leading 7 Plasma Fractionation Market: Ranking, Company, FY2017 Total Company Sales $m, FY2017 Sales in the Market $m, Share of FY2017 Total Sales from Sales in the Market $m, Primary Market Specialisation
Table 10.2 CSL Limited Profile 2017
Table 10.3 CSL Limited Total Company Sales 2013-2017 ($m), AGR %)
Table 10.4 CSL Limited Sales in the Plasma Fractionation Market 2016 -2017 ($m, AGR %)
Table 10.5 CSL Limited Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.6 Shire Profile 2017
Table 10.7 Shire Total Company Sales 2013-2017 ($m, AGR %)
Table 10.8 Shire Sales in the Plasma Fractionation Market 2016 -2017 ($m), AGR %)
Table 10.9 Shire Net Income / Loss 2013-2017 ($m), AGR %)
Table 10.10 Grifols Profile 2017
Table 10.11 Grifols Total Company Sales 2013-2017 ($m), AGR %)
Table 10.12 Grifols Sales in the Plasma Fractionation Market 2016 -2017 ($m), AGR %)
Table 10.13 Grifols Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.14 OctaPharma Profile 2017
Table 10.15 OctaPharma Total Company Sales 2013-2017 ($m, AGR %)
Table 10.16 OctaPharma Sales in the Plasma Fractionation Market 2016 -2017 ($m, AGR %)
Table 10.17 OctaPharma Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.18 Biotest Profile 2017
Table 10.19 Biotest Total Company Sales 2013-2017 ($m, AGR %)
Table 10.20 Biotest Sales in the Plasma Fractionation Market 2016 -2017 ($m, AGR %)
Table 10.21 Biotest Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.22 LFB Profile 2017
Table 10.23 LFB Total Company Sales 2013-2017 ($m, AGR %)
Table 10.24 LFB Sales in the Plasma Fractionation Market 2016 -2017 ($m, AGR %)
Table 10.25 LFB Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.26 KEDRION Profile 2017
Table 10.27 KEDRION Total Company Sales 2013-2017 ($m, AGR %)
Table 10.28 KEDRION Sales in the Plasma Fractionation Market 2016 -2017 ($m, AGR %)
Table 10.29 KEDRION Net Income / Loss 2013-2017 ($m, AGR %)
Table 10.30 Other Companies Involved in the Plasma Fractionation Market 2017 (Company, Submarket Involvement, Location)
Table 11.1 Global Plasma Fractionation Market Forecast: Revenues ($m) 2017, 2028 and CAGR 2018-2028 (%)
List of Figures
Figure 2.1 Global Plasma Fractionation Market Segmentation Overview
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
The global Single-Use Bioprocessing Probes & Sensors market was valued US$2,493.8 million in 2022 and is projected to grow at a CAGR of 15.2% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
